argenx(US:ARGX) Globenewswire·2026-01-05 06:00Core Viewpoint - The leadership transition at argenx SE is aimed at preparing the company for its next phase of growth, with Karen Massey stepping up as CEO and Tim Van Hauwermeiren becoming Chairman of the Board [1][2] Group 1: Leadership Changes - Karen Massey will transition from Chief Operating Officer to Chief Executive Officer and Executive Director [1] - Tim Van Hauwermeiren will move from Chief Executive Officer to Non-Executive Director and Chairman of the Board, succeeding Peter Verhaeghe, who is retiring [1][2] - The leadership changes are subject to shareholder approval at the Annual General Meeting scheduled for May 6, 2026 [1] Group 2: Strategic Vision - The leadership evolution is seen as a natural step towards a long-term future that is patient-focused and sustainable [2] - Tim Van Hauwermeiren expressed confidence in Karen Massey’s ability to lead the company forward, highlighting her impact since joining argenx [2] - Karen Massey emphasized her commitment to executing Vision 2030 and building a future-proof biotech company [2] Group 3: Company Overview - argenx is a global immunology company focused on improving the lives of individuals with severe autoimmune diseases [3] - The company collaborates with leading academic researchers through its Immunology Innovation Program to develop novel antibody-based medicines [3] - argenx is known for commercializing the first approved neonatal Fc receptor blocker and is exploring its potential in various serious autoimmune diseases [3]